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“We shape our buildings, and afterwards 
our buildings shape us.”
Winston Churchill
Introduction
Th e research of this decade has yielded substantial 
improvements in the delivery of and technology with 
which to provide care for critically ill intensive care unit 
(ICU) patients. Garnering less attention from the medical 
and scientiﬁ c community is the environment in which 
that care is provided, which remains impersonal, noisy, 
and over illuminated. Noticeably, the nursing and busi-
ness literature is replete with studies on the matter [1,2].
Th is discussion will focus on the available evidence 
regarding associations between the ICU environment, 
speciﬁ cally light, and patient outcome. Deﬁ nitions of 
light and the biology, including neural, hormonal, and 
immunologic mechanisms, by which it aﬀ ects the body 
will be initially emphasized. An integrative commentary 
will be presented at the conclusion. Because of con-
straints, the focus is upon the critically ill patient, 
recognizing that much of what will be discussed is 
equally applicable to the healthcare provider.
Light
Sunlight reaching the earth’s surface is categorized by 
eﬀ ective wavelength: ultraviolet B (UV-B, 280–315 nm), 
ultraviolet A (UV-A, 315–400 nm), visible light (400–
760 nm), and infrared light (760 nm × 1.06 nm) [3]. Of 
these four categories, visible light is essential for vision 
and resetting of the circadian clock through photo-
receptors in the retina [4]. Exposure to UV-B radiation 
induces biological changes in the integument, such as 
sunburn, skin cancers and, as will be discussed, immuno-
sup pression [5]. UV-A is involved in carcinogenesis 
through the generation of highly reactive chemical 
intermediates and lipid peroxidation [6].
Light is measured using either radiometry (an analysis 
of the entire visible and non-visible wavelength spectra) 
or photometry [7]. Both methods provide valuable and 
distinct information that deﬁ nes light. Photometry, a 
perception of brightness as seen by the human eye, is 
performed with a lux meter in units called lux. For 
comparison purposes, moonlight is 0.5 to 1 lux, a bright 
oﬃ  ce is 400 lux, and a sunny day in spring is 32,000 to 
60,000 lux [8]. Nocturnal light levels vary among ICUs 
with mean maximum levels ranging from 1 to 1,400 lux 
[8]. During the performance of procedures (e.g., catheter 
insertion), light devices can easily deliver > 10,000 lux.
Light aﬀ ects the body by receptor stimulation through 
the eyes (retina) and through the skin. Th e classical visual 
sensory system is comprised of photoreceptor cells of 
rods (low-level light) and cones (sharpness, detail, and 
color vision). Th e impact of a photon of light generates 
rhodopsin, thus creating electrical impulses in the optical 
nerve that converge within the visual cortex and are 
interpreted as ‘vision’ [4]. For more than 150 years, scien-
tists considered rods and cones to be the sole 
photoreceptor cells in the eye. With the discovery of a 
novel, third type of retinal photoreceptor in mammals 
[9], a new retinohypothalamic pathway was described, 
providing evidence of a pathway mediating the biological 
but non-visual eﬀ ects of light.
The biological perspective: non-visual eff ects of light
Th e health eﬀ ects of light are realized through several 
biological processes additional to and independent of the 
ability of visually perceiving the external world [10]. Only 
recently have we acquired deeper insight into the bio-
logical mechanisms regulating these non-visual eﬀ ects. 
Fundamental to this understanding is an appreciation of 
how light controls the biological clock and regulates 
important hormones through seasonal photoperiods 
(duration of an organism’s daily exposure to light) and 
regular light-darkness rhythms.
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Circadian pathways
Circadian rhythms are cycles of physiologic processes 
and behaviors driven by an endogenous oscillator having 
a period of approximately (circa) one day (diem). Th e 
most evident circadian rhythm in humans is the sleep-
wake cycle. Other circadian rhythms include body temp-
era ture, release of hormones (e.g., melatonin, cortisol), 
and gene expression. Th ese rhythms persist with a near 
24-h period even in the absence of time-of-day infor-
mation [11]. Environmental stimuli can reset the phase of 
the circadian pacemaker, light being the ultimate entrain-
ment signal [12]. A change in the timing of the light-dark 
cycle (e.g., nocturnal light exposure) will result in a shift 
in the phase of circadian rhythms that can only be 
detected in the next circadian cycle. However, the eﬀ ects 
on circadian physiology (e.g., body temperature and 
melatonin suppression) can be observed during or imme-
diately after the light exposure [13]. In the case of a 
disruption of the rhythm, exposure to bright light in the 
morning will help to restore it [14].
Th e suprachiasmatic nucleus in the anterior hypothala-
mus is the circadian pacemaker [15]. It contains cells that 
are able to express sustained periodicity, even in vitro. 
Functional neuroimaging studies have demonstrated that 
light quickly activates alertness-related subcortical struc-
tures in the suprachiasmatic nucleus and a sequence of 
intermediate connections terminating in the pineal gland 
that underlie the circadian-based synthesis and release of 
melatonin [16]. Th e thalamus functions as an interface 
between alertness, cognition, and the eﬀ ects of light [17], 
anatomically connecting with the frontal, temporal and 
cerebral cortex (except for the olfactory system), cerebel-
lum, and basal ganglia. It regulates the ﬂ ow of informa-
tion from the retina to the visual cortex or between 
cortical areas [18]. Light stimulates a retinal photo-
receptor system expressing melanopsin, a photopigment 
produced in the human inner retina and directly 
activated by light [4]. Interestingly, even extensive degra-
dation of the photoreceptor apparatus does not eliminate 
the synthesis of melanopsin [10]. Subsequent signals are 
channeled to the suprachiasmatic nucleus via the 
retinohypothalamic pathway. Melanopsin plays a key role 
in mediating the non-visual eﬀ ects of light and renders a 
small subset of retinal ganglion cells intrinsically photo-
sensitive (ipRGC) with maximal sensitivity to blue light 
[11]. Th e eﬀ erent projections of the ipRGCs include 
multiple hypothalamic, thalamic, striatal, brainstem and 
limbic structures, which govern circadian cycles, body 
temperature, and alertness [17].
Th e ability of light to modulate cortical activity and 
circadian rhythm is deﬁ ned, in part, by the duration, 
intensity and wavelength of the lighted stimulus [17,19]. 
Biological processes dictate that non-visual responses are 
maximally sensitive to blue light (459–483 nm), in 
contrast to the green (~550 nm) spectral sensitivity of 
classical visual photoreceptors [11,13]. Blue light most 
powerfully changes the rhythm of melatonin and cortisol 
secretion, acutely suppressing melatonin. It also elevates 
body temperature and heart rate, reduces subjective 
sleepiness and improves alertness [17,20,21]. In one 
study, oﬃ  ce workers were exposed to two new lighting 
conditions for 4 weeks: A blue-enriched white light or a 
white light that did not compromise visual performance. 
Blue-enriched white light signiﬁ cantly heightened 
subjective measures of alertness, positive mood, perfor-
mance, and concentration while reducing evening fatigue, 
irritability, and eye discomfort. Daytime sleepi ness was 
reduced and the quality of subjective nocturnal sleep was 
improved [21]. Th us, evidence conﬁ rms that for the 
human brain, the absence of blue light, at least from a 
circadian point of view, is eﬀ ectively darkness [22].
Melatonin
Most of the eﬀ ects of the photoperiod are mediated by 
melatonin, the hormone secreted by the pineal gland in 
response to darkness. Th is hormone is synthesized within 
the pineal gland from the essential amino acid tryptophan 
through enzymatic processes of 5-hydroxylation and 
decarboxylation that yield 5-hydroxytryptamine (5-HT 
or serotonin). During daylight, serotonin remains stored 
in pinealocytes and unavailable for conversion to mela-
tonin. With darkness, postganglionic sympathetic out-
ﬂ ow to the pineal gland releases serotonin and induces 
enzymatic conversion of serotonin to melatonin [23].
Melatonin plays an equally important role in the 
adaptive response of an organism to environmental chal-
lenges. Experimental studies have shown that binding of 
melatonin to speciﬁ c receptors in antigen-activated Type 1 
T-helper cells (Th -1) upregulates pro-inﬂ ammatory cyto-
kine production (such as interferon [IFN]-χ and inter-
leukin [IL]-2) [24] and enhances the production of IL-1, 
IL-6 and IL-12 in human monocytes [25–27]. It is 
believed that it may increase phagocytosis and antigen 
presentation [28]. Animal models have demonstrated 
that melatonin has a protective eﬀ ect in mice against 
lethal viral encephalitis [29], infectious hepatitis [30], and 
hemorrhagic [31] or septic [32] shock. In this context, 
melatonin has been shown to prevent endotoxin-induced 
circulatory failure in rats through inhibition of tumor 
necrosis factor (TNF)-α, and to reduce post-shock levels 
of IL-6, superoxide production in the aorta, and inducible 
nitric oxide synthase (iNOS) in the liver [32] (Table 1).
Th ese data suggest that the winter immunoenhance-
ment paradigm [38] could explain photoimmunomodu-
latory processes in animals and be applicable to patients 
contending with severe illnesses. Th is theory was 
developed in the context of lower mammals and proposes 
that in environments that undergo seasonal changes in 
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energy availability, selection should favor individuals that 
support enhanced immune function during the winter 
(shorter days). Photoperiodic information is used to 
bolster immune function in anticipation of winter [38]. 
Redirecting metabolic energy stores toward improved 
immune function should enable animals to contend 
better with the stressors (e.g., decreased temperature and 
food availability) of winter, a time of the year when 
reproductive eﬀ orts are less likely to succeed. Conversely, 
during the breeding season (longer days), energetic trade-
oﬀ s favor reproduction, and immune function is relatively 
impaired [34].
A critically ill patient lies in a winter-like condition 
because energy resources are severely compromised. 
More over, immunity is impaired as the body is contend-
ing with many severe insults. Th e physiological regulation 
of melatonin secretion by darkness and light is probably 
abolished due to loss of the circadian rhythm, a 
consequence of the altered patterns of illumination in 
most ICUs [39]. Th us, this pathway is directly linked to 
the inﬂ ammatory response and, ultimately, a patient's 
outcome. It would be highly desirable to direct resources 
toward enhancing the immune system so as to enable the 
patient with a better chance to overcome this biological 
‘severe weather'. Th is might be accomplished by restoring 
a circadian light/darkness cycle, by providing longer 
periods of darkness and less hours of light in the ICU. 
Th e use of `virtual darkness' by providing amber lenses to 
ﬁ lter the impact of electrical light, particularly ubiquitous 
blue light, could attain the objective [22]. Beyond its 
antioxidant properties, the role of melatonin as a 
systemic immunoregulatory agent sensitive to exogenous 
regulation is an exciting idea to be tested in controlled 
trials of human sepsis [40].
Cortisol
Cortisol is a steroid hormone that inﬂ uences metabolic, 
immunologic, muscle and brain functions. Its secretion is 
regulated primarily by the hypothalamic-pituitary-
adrenal (HPA) axis through release of corticotrophin 
releasing hormone (CRH) from the hypothalamus and 
adrenocorticotrophic hormone (ACTH) from the 
anterior pituitary gland [41]. Cortisol negatively feeds 
back to the hippocampus, hypothalamus, and the 
anterior pituitary, inhibiting CRH and ACTH. Th e supra-
chiasmatic nucleus regulates the circadian rhythm of 
corticosteroids [42]. Th us, cortisol decreases across the 
habitual waking day to attain a nadir near bedtime. 
Concentrations subsequently increase during the dark-
ness of night and peak near arousal, regardless of 
continuous wakefulness or sleep [43]. Superimposed on 
this rhythm are ﬂ uctuations associated with the pulsatile 
or acute release of cortisol by diverse factors such as 
anxiety, stress, immune challenge, blood glucose levels, 
sleep onset, sleep loss, and exposure to light [44].
In sepsis, the HPA axis aﬀ ects inﬂ ammation by modu-
lat ing leukocytes, cytokines and NO synthesis [45]. 
Th rough negative feedback, inﬂ ammatory cytokines may 
suppress sensitivity to ACTH [46], resulting in adrenal 
insuﬃ  ciency [47], or compete with intracellular gluco-
corti coid receptor function, thereby causing peripheral 
tissue glucocorticoid resistance [48].
Th e relationship between light and plasma levels of 
cortisol is complex. Inconsistent results have been 
attributed to diﬀ erences in light intensity and wavelength, 
and the timing of application as it relates to the circadian 
cycle [44]. More recent studies, however, provide compel-
ling evidence that light is a strong determinant of cortisol 
concentration. Bright light exposure (up to 10,0000 lux) 
elicited a signiﬁ cant suppressive eﬀ ect when applied 
either on the rise or descent phase of cortisol rhythm. 
Lower intensities (less than ~5,000 lux) failed to induce 
signiﬁ cant changes [44]. Th ese results would be consis-
tent with the ﬁ ndings of light-intensity response curves 
for melatonin suppression [49]. In contrast to melatonin’s 
responses, both blue and red lights increased cortisol 
plasma levels at night [50].
A multisynaptic neural pathway (retina-suprachias-
matic nucleus-adrenal gland) that bypasses the HPA axis 
is considered responsible for the acute inﬂ uence of light 
on corticosteroid concentrations. Th ese conclusions 
stem, in part, from the observation that cortisol varia-
tions are reported to be dependent upon an intact 
suprachiasmatic nucleus and not related to changes in 
Table 1. Examples of immune eff ects associated with photoperiods
Tumorigenesis was reduced and basal lymphocyte proliferation or mitogen-induced splenocyte proliferation were promoted with shorter days (rodents) [33, 34]
Seasonal attenuation of the immune response to Gram-negative infections was observed when shortening the length of days in a rodent model [35]
Measures of immune cell counts, lymphoid organ weights or T cell-dependent antibody responses to xenogeneic antigens were generally enhanced by short 
photoperiod of winter [36]
Exposure to short days increased mass of the spleen and enhanced the total number of leukocytes and lymphocytes when only photoperiod was manipulated [20]
Circulating numbers of leukocytes, neutrophils, and lymphocyte proliferation in response to mitogens were higher in winter than in the summer in a primate 
model [37]
Seasonal changes in immune parameters were observed, with enhancement of specifi c immune responses during autumn and winter compared with spring 
and summer, in animal models (rodents, rabbits, dogs and primates) [20]
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ACTH levels [51]. Th us, aspects of a lighted environment 
could be adjusted to elicit this HPA-independent res-
ponse. In a critically ill patient, this approach could lessen 
a relative or overt adrenal insuﬃ  ciency and constitutes an 
interesting idea worthy of future study.
Photo-immunomodulation
Seasonal rhythms and ﬂ uctuations in innate and acquired 
immune responses have been documented in many 
species [52,53]. Profound but selective eﬀ ects on immune 
function are associated with the prevailing photoperiod 
[36,54]. T cell immunity is depressed in most species in 
the winter, even when natural light sources and exposure 
are kept constant [20,54]. Experimental data, however, 
show that immune cell numbers and immunoglobulin 
concentrations vary with respect to the season or day 
length [34,54] even during the winter. Higher leukocyte 
counts are noted with less hours of light [20,54], 
demonstrating that the photoperiod may also inﬂ uence 
the functional capabilities of immune cells. Short days 
selectively enhance natural killer (NK) basal proliferative 
capacity and cell activity [34]. In contrast, in the same 
rodent model, phagocytic and granulocyte oxidative 
burst activity are reduced during short, by comparison to 
long, days [20,55]. Collectively, these results conﬁ rm 
reduced immune function in winter compared to 
summer, but with enhanced immune function in short 
winter-like photoperiods compared to long summer-like 
day lengths [56] (Table 1). Th e net elevated immune 
function in short days is thought to counteract the 
suppressive eﬀ ects of environmental stressors such as 
low ambient temperature on immune function [20]. 
Th ese facts raise many questions for the management of 
critically ill patients. Is there a consistent seasonality on 
the outcomes of critically ill patients? Should we shorten 
the day length for the most seriously ill septic patients in 
the ICU to enhance their immunity? Th ese concepts 
await further investigation.
Central pathways: the infl ammatory refl ex
A recent major advance in our understanding of the 
immune response during severe sepsis came with the 
identiﬁ cation of the cholinergic anti-inﬂ ammatory path-
way [57]. Cytokine release can be controlled at multiple 
levels, including the central nervous system (CNS). 
Endotoxin and products of inﬂ ammation stimulate aﬀ er-
ent neural signals in the vagus nerve that induce acute-
phase responses, fever, and the upregulation of IL-1β in 
the brain. Concomitantly, aﬀ erent vagus nerve signals are 
transmitted to the medullary reticular formation, locus 
ceruleus, hypothalamus, and dorsal vagal complex, lead-
ing to an increase in ACTH from the anterior pituitary 
gland [57]. Th is stimulates an increase in systemic gluco-
corticoid levels, thereby inhibiting pro-inﬂ ammatory 
cytokine release [58]. Alternatively, ascending sensory 
ﬁ bers of the vagus nerve that synapse in the nucleus 
tractus solitarius of the upper medulla can inhibit cyto-
kine release. Like other reﬂ ex arcs, the inﬂ ammatory 
reﬂ ex is comprised of a sensory aﬀ erent arm (described 
above) and an eﬀ erent motor arm that controls a rapid 
and opposing reaction [57]. Th is cholinergic anti-inﬂ am-
matory eﬀ erent pathway inhibits inﬂ ammation. Eﬀ erent 
vagus nerve signals release acetylcholine (ACh) in organs 
of the reticuloendothelial system, including the spleen, 
liver, and gastrointestinal tract [57]. ACh binds to the 
nicotinic receptor (α7nAChR) expressed on the surface 
of activated macrophages and other immune cells, which 
inhibits nuclear factor κB (NF-κB) and attenuates 
cytokine production. Th e biological relevance of this 
pathway was made manifest by murine endotoxemia 
studies demonstrating that stimulation of the eﬀ erent 
vagus nerve inhibited TNF-α release, prevented shock, 
and improved survival [59]. Th e vagal inﬂ ammatory 
reﬂ ex also regulates localized inﬂ ammation. In a murine 
model of arthritis, vagus nerve stimulation inhibited 
inﬂ ammation and suppressed the development of paw 
swelling [60]. In the lungs, pharmacological α7nAChR 
stimulation correlated with reduced lipopolysaccharide 
(LPS)-induced neutrophil recruitment [61]. Collectively, 
these studies suggest that either by electrical or chemical 
intervention, this inﬂ ammatory reﬂ ex pathway can be 
modiﬁ ed to modulate the inﬂ ammatory response to 
injury or infection [62].
Consistent evidence supporting a link between sunlight 
exposure and the inﬂ ammatory reﬂ ex is lacking, however. 
Th e eﬀ erent arm of the inﬂ ammatory reﬂ ex regulates 
TNF-α production in the spleen via two serially con-
nected neurons: One preganglionic, originating in the 
dorsal motor nucleus of the vagus nerve (parasympa-
thetic), and the second postganglionic, originating in the 
celiac-superior mesenteric plexus, and projecting in the 
catecholaminergic splenic (sympathetic) nerve [63]. 
Th erefore, one of the most crucial components of the 
eﬀ erent inﬂ ammatory reﬂ ex is catecholaminergic in 
nature. As the suprachiasmatic nucleus balances sympa-
thetic and parasympathetic output to peripheral organs 
[64], one might speculate that the eﬀ erent arm of the 
inﬂ ammatory reﬂ ex could be directly activated or 
inhibited by light exposure, thereby establishing a neural 
link between the retinohypothalamic pathway and the 
inﬂ ammatory reﬂ ex. As the non-visual retinohypo-
thalamic pathway’s net eﬀ ect is to enhance immunity, 
this inﬂ ammatory reﬂ ex mechanism could constitute a 
counterregulatory mechanism (Fig. 1).
Skin pathways: immunosuppression by ultraviolet B radiation
Th e skin represents an important interface between the 
external environment and internal tissues and is 
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constantly bathed in sunlight. Both direct (skin-
mediated) and indirect immunomodulation have been 
described. Visible light (400–700 nm) can penetrate the 
epidermal and dermal layers and directly interact with 
circulating lymphocytes. UV-B and UV-A radiation alter 
normal human immune function predominantly via a 
skin-mediated response [20]. Epidermal Langerhans cells 
survey invading agents and transmit the information into 
immune cells. After engulﬁ ng exogenous antigen, these 
sentinels migrate to draining lymph nodes and present 
the processed antigen to T cells, thereby inducing speciﬁ c 
T cell diﬀ erentiation and T cell activation. Ionizing and 
non-ionizing UV radiation (below 400 nm) inhibit this 
antigen presentation via induction of suppressive 
keratinocyte-derived cytokines. Th is reduces eﬀ ector T 
cell proliferation and activity and induces immuno-
tolerance [65]. In addition, regulatory T cells (Treg) serve 
important immunoregulatory and immunosuppressive 
functions. Induced by UV radiation, Treg cells release 
IL-10, leading to immunosuppression. Th us, functional 
alterations of epidermal Langerhans cells and a systemic 
increase in Treg cells couple the epidermis to local and 
systemic immunosuppression [66]. Th e balance between 
the numbers and function of regulatory and eﬀ ector 
T  cells is crucial for the immune system. Although the 
molecular mechanisms underlying the expansion of 
regulatory T cells after UV exposure are largely unknown, 
vitamin D3 has been recently shown to upregulate the 
RANKL (receptor activator for NF-κB ligand) expression 
that activates Langerhans cells [65]. Th is should be 
carefully considered when managing critically ill patients 
in an ICU with windows with no UV protection. 
Although not subjected to rigorous evaluation, UV-
induced immunosuppression could play an adverse role 
in a critically ill patient (Fig. 1).
Vitamin D3, 1,25(OH)D2, and cathelicidin
Vitamin D belongs to the family of steroid hormones. 
Exposure to UV-B radiation of 290–315 nm converts 
7-dehydrocholesterol to pre-vitamin D3. Pre-vitamin D 
rapidly undergoes a thermally induced isomerization to 
form vitamin D3. D3 enters the circulation where it 
undergoes hydroxylation in the liver by vitamin D-25-
hydroxylase and in the kidney by the 25-hydroxyvitamin 
D-1-alpha-hydroxylase (1α-OHase), thus forming 1–
25(OH)D2. Th e classic function of vitamin D is to enhance 
intestinal absorption of calcium by regulating several 
calcium transport proteins in the small intestine [67].
Cells of the immune system also possess 1α-OHase and 
the vitamin D receptor (VDR) and, thus, are able to 
Figure1. Integrative diagram of the visual and non–visual pathways that mediate the biological and behavioral eff ects of sunlight 
exposure in a critically ill patient.
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produce the hormonally active form. Macrophages 
produce the antimicrobial peptide, cathelicidin LL-37, in 
response to endogenously produced 1,25(OH)D2 to 
enhance innate immunity [67]. Th e antimicrobial peptide, 
LL-37, is the only known member of the cathelicidin 
family expressed in humans. It is a multifunctional host 
defense molecule essential for normal immune responses 
to infection and tissue injury. LL-37 peptide exhibits 
strong activity against common ICU bacterial strains, 
including Escherichia Coli, Pseudomonas aeruginosa, 
Klebsiella pneumoniae, Staphylococcus aureus (methicillin-
resistant [MRSA] and non-MRSA), and Neisseria gonor-
rhoeae. It prevents the immunostimulatory eﬀ ects of 
bacterial cell wall molecules such as LPS and can, there-
fore, protect against lethal endotoxemia [68]. Cellular 
production of LL-37 is aﬀ ected by multiple factors, 
including bacterial products, host cytokines, availability 
of oxygen, and sun exposure through the activation of 
CAP-18 gene expression by vitamin D3 [68]. As sunlight 
within the UV-B spectrum induces immunosuppression 
and heightens vulnerability to infection, 1,25(OH)D2 
potentially balances this eﬀ ect by stimulating the 
synthesis of LL-37 in the skin and circulating phagocytic 
cells [69]. Recently, lower circulating levels of 25(OH)D 
and vitamin D binding protein have been observed in 
critically ill patients compared to healthy controls [70]. 
Th us, it might be concluded that optimal function of our 
innate immune system requires some necessary amount 
of vitamin D and, accordingly, of sunlight (Fig. 1). Th is is 
a strong reason for providing septic patients with con-
trolled exposure to direct sunlight.
The biological perspective: visual eff ects of light
From the Greek Asclepieia to the monastic Middle Age 
inﬁ rmaries, traditions of complementary medicine and 
holistic healing have been rooted in the provision of 
medical care. Pleasant views were obligatory character-
istics of places designed to give shelter and provide care 
for diseased people. It is now appreciated that the visual 
environment can powerfully inﬂ uence the atmosphere 
and visual impression of the workplace. Properly 
designed, the overall working environment can have a 
stimulating eﬀ ect on the people working within it [71]. 
Interior daylight contributes substantially to the 
perceived quality of the working environment. Light is 
mood enhancing and fosters visual and general health 
[71]. An important benchmark in the history of integrat-
ing nature into the care of patients was made by Roger 
Ulrich in 1984 [72]. Post-surgical patients with a view of 
nature suﬀ ered fewer complications, used less pain 
medica tion, and were discharged sooner than those with 
a view of a brick wall. Th is pioneering study provided the 
ﬁ rst formal scientiﬁ c evidence that ‘healing environ-
ments’ beneﬁ cially alter health. In the following years, 
many other groups from across the world have reported 
the health beneﬁ ts associated with views of nature, 
daylight exposure and related elements [73] (Table 2). 
Based on these ﬁ ndings, many have proposed that expo-
sure to daylight be considered as a medical intervention 
for critical care patients. Nevertheless, such studies have 
not been yet performed though the concept warrants 
further study.
The behavioral perspective
People prefer daylight to electric lighting as their primary 
source of illumination [78]. Most prefer to work and live 
in buildings illuminated by daylight as it provides 
psychological comfort, increased satisfaction in the work 
environment, and visual and general health [79]. A 
window providing a beautiful view of the surrounding 
landscape or of the sky and mountains might bolster 
psychological coping and thereby facilitate healing [71], 
all through a sensation of well-being. Well-being can be 
deﬁ ned in terms of an individual’s physical, mental, 
social, and environmental status. Th ese aspects interact 
with each other and possess diﬀ ering levels of importance 
speciﬁ c to that individual (Table 3). Almost all of these 
components are present in the critically ill patient.
Apart from the biological considerations previously 
discussed, the positive sensations elicited by a daylighted 
view might enable a patient to more appropriately cope 
with critical illness. Psychologists make an important 
distinction between short-term positive emotions (hedonic 
well-being) and psychological (eudaimonic) well-being. 
Eudaimonic well-being has to do with the realization of 
personal potential and purpose in life, and is mainly 
determined by childhood social circumstances and the 
development of loving and trusting relationships early in 
life [81]. Th erefore, it is not subject to simple modiﬁ  ca-
tions through daily life experiences. Conversely, hedonic 
Table 2. Some benefi cial health eff ects of light exposure reported in the literature
Light can alleviate seasonal depression [74]
Sunlight exposure improves cognitive function among depressed people in a dose-response relationship [75]
Light regulates melatonin, which has paramount immunomodulatory eff ects and has been shown to reduce breast cancer growth [20]
Female patients with a fi rst cardiac attack treated in sunny rooms had a shorter stay than female patients treated in dull rooms and mortality in both sexes was 
consistently higher in dull rooms than in sunny rooms [76].
Absence of visible daylight in the room is signifi cantly associated with delirium and higher risk of dementia in intensive care patients [77]
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well-being is related to experiences of happiness and 
satisfaction and is a short-term sensation. Several authors 
have described the short-term beneﬁ ts of positive 
emotions and attitudes on reducing the cardiovascular 
response to stress [82], lowering pain ratings and sensi-
tivity [83], and volunteers trained in meditation produced 
high levels of immunity to inﬂ uenza [84]. Th us, the 
appreciation of sunlight may impact favorably upon the 
health of a critical patient through this shorter-term 
perspective (Fig. 1).
The holistic perspective
No single factor is responsible for any given health 
circum stance or condition. Th is common-sense state-
ment was conceptually developed by Moos in 1976 [85] 
and is called the social-ecological framework. Th is model 
views a speciﬁ c situation as the sum product of the inter-
action of many factors ordered in ﬁ ve levels: Individual, 
interpersonal, community-level, societal, and policy. 
Environ ment integrates into the third and fourth categories.
Humans can modify almost every aspect of their world 
to create hospitable places within which to work, play 
and live. Th ey enjoy and seek the pleasant emotions that 
a beautiful landscape and a warm sunlight nourish. Over 
time, however, we have become extremely dependent 
upon a man-made environment. Artiﬁ cial light consti-
tutes an indispensable part of our modern lives. Conse-
quently, seasons, daylight hours and healthy sleep-waking 
cycles are less a part of our existence. But physiology 
reminds us that maintaining a balanced sleep-wake cycle 
is essential to survive. It allows animals to enhance their 
immunity through light-mediated mecha nisms even in 
adverse environmental conditions.
When a healthy individual suﬀ ers an acute serious 
illness, these ancient survival mechanisms reacquire 
relevance. Th e biologic environment becomes hostile and 
the patient starts to struggle with the most atavistic 
challenge he/she could face: Th e ﬁ ght for survival. At this 
point, the provision of professional intensive care must 
include elements apart from standard medical care. It 
should consider the deliberate intention to modulate the 
patient’s immune response via activation of visual and 
non-visual pathways. Modiﬁ cation of light settings and 
timing becomes a fundamental component in this 
approach, as well as prudent exposure to sunlight for 
some hours. We cannot assure that providing sunlight 
exposure to critically ill patients and shortening the daily 
time of exposition to light will result in improved 
survival. Th e ﬁ nal outcome will emerge from a dynamic 
ongoing process in which personal and environmental 
factors will exert inﬂ uence upon each other according to 
the social-ecological framework. However, the systemic 
and local immunomodulatory eﬀ ects and the positive 
emotions elicited by this sensorial experience give us a 
solid rationale to integrate them as key components in 
the delivery of care in the ICU.
Conclusion
Clearly light has the very real potential to alter the course 
of disease and the behavior of persons providing care. 
Although we have a deeper understanding of the bio-
logical mechanisms involved in the visual and non-visual 
eﬀ ects of light, and the psychological and behavioral 
elements of the complex interaction between light 
exposure and health outcomes, it is far from complete. 
Th ere are still many nebulous aspects, and with each step 
of understanding, several new questions arise, particu-
larly in the context of critical illness. How does illness 
alter the neural and endocrine pathways governing the 
biological eﬀ ects of light? Do measures to engage the 
physiologic and neural feedback loops enhance, hinder, 
or fail to inﬂ uence their actions? What are the eﬀ ects of 
blue and green light wavelengths in a patient that is 
sedated and intubated? What happens to the biologic 
rhythms and immune responses if our critically ill patient 
rests in a room without windows, even though it is a 
greatly illuminated one? As artiﬁ cial light sources in ICUs 
fail to account for retinal spectral sensitivity and the 
circadian clock, are our artiﬁ cially lighted work environ-
ments leaving our patients and healthcare providers blue 
light ‘deprived’? Hopefully, for these and many other 
ques tions, future studies will enlighten us as to the 
beneﬁ ts of returning natural light and nature to the 
bedside.
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